Pre-made Upifitamab benchmark antibody ( Whole mAb, anti-SLC34A2 therapeutic antibody, Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-602

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-602 Category Tag

Product Details

Pre-Made Upifitamab biosimilar, Whole mAb, Anti-SLC34A2 Antibody: Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Upifitamab biosimilar, Whole mAb, Anti-SLC34A2 Antibody: Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM therapeutic antibody

INN Name

Upifitamab

Target

SLC34A2

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I/II

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2019

Companies

Mersana Therapeutics

Conditions Approved

NA

Conditions Active

Non-small cell lung cancer,Ovarian cancer

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

SLC34A2

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide